JP2018517715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517715A5 JP2018517715A5 JP2017563337A JP2017563337A JP2018517715A5 JP 2018517715 A5 JP2018517715 A5 JP 2018517715A5 JP 2017563337 A JP2017563337 A JP 2017563337A JP 2017563337 A JP2017563337 A JP 2017563337A JP 2018517715 A5 JP2018517715 A5 JP 2018517715A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- dosage form
- particles
- solid pharmaceutical
- estetrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 57
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 claims description 28
- 229950009589 estetrol Drugs 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 6
- -1 estetrol ester Chemical class 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 25
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- 229920000881 Modified starch Polymers 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 235000014633 carbohydrates Nutrition 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004368 Modified starch Substances 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 229960005168 croscarmellose Drugs 0.000 claims 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 235000019426 modified starch Nutrition 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000000811 xylitol Substances 0.000 claims 2
- 235000010447 xylitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 2
- 229960002675 xylitol Drugs 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000010419 agar Nutrition 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000748 compression moulding Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 125000003071 maltose group Chemical group 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172755.9 | 2015-06-18 | ||
| EP15172755 | 2015-06-18 | ||
| PCT/EP2016/064181 WO2016203044A1 (en) | 2015-06-18 | 2016-06-20 | Orodispersible tablet containing estetrol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517715A JP2018517715A (ja) | 2018-07-05 |
| JP2018517715A5 true JP2018517715A5 (enExample) | 2020-11-19 |
| JP6813150B2 JP6813150B2 (ja) | 2021-01-13 |
Family
ID=53476702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563337A Active JP6813150B2 (ja) | 2015-06-18 | 2016-06-20 | エステトロールを含有する口腔内崩壊錠 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10888518B2 (enExample) |
| EP (1) | EP3310346B1 (enExample) |
| JP (1) | JP6813150B2 (enExample) |
| CN (1) | CN107750157B (enExample) |
| CA (1) | CA2988362C (enExample) |
| CY (1) | CY1124052T1 (enExample) |
| DK (1) | DK3310346T3 (enExample) |
| ES (1) | ES2877476T3 (enExample) |
| HR (1) | HRP20210555T1 (enExample) |
| HU (1) | HUE054551T2 (enExample) |
| LT (1) | LT3310346T (enExample) |
| MA (1) | MA44206B1 (enExample) |
| MD (1) | MD3310346T2 (enExample) |
| PL (1) | PL3310346T3 (enExample) |
| PT (1) | PT3310346T (enExample) |
| RS (1) | RS61777B1 (enExample) |
| SI (1) | SI3310346T1 (enExample) |
| SM (1) | SMT202100350T1 (enExample) |
| WO (1) | WO2016203044A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012264602B2 (en) | 2011-06-01 | 2017-03-09 | Estetra Srl | Process for the production of estetrol intermediates |
| WO2012164095A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| UA123099C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована в порожнині рота одиниця дозування, яка містить естетрольний компонент |
| MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| HRP20210668T1 (hr) * | 2015-06-18 | 2021-05-28 | Estetra Sprl | Orodisperzibilna tableta koja sadrži estetrol |
| US20160367567A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| EP3647413A1 (en) * | 2018-10-31 | 2020-05-06 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) | Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| JP7588140B2 (ja) * | 2019-09-27 | 2024-11-21 | インダストリアレ チミカ ソシエタ ア レスポンサビリタ リミタータ | （１５α，１６α，１７β）－エストラ－１，３，５（１０）－トリエン－３，１５，１６，１７－テトロール（エステトロール）および当該製法の中間体を調製するためのプロセス |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022069956A1 (en) * | 2020-09-29 | 2022-04-07 | Millicent Pharma Limited | Orodispersible formulations |
| EP4243602A4 (en) | 2020-11-16 | 2024-11-13 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
| US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
| US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
| JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
| WO2001040255A2 (en) | 1999-12-02 | 2001-06-07 | Akzo Nobel N.V. | 14,15-beta-methylene substituted androgens |
| US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| ES2278924T3 (es) * | 2001-05-18 | 2007-08-16 | Pantarhei Bioscience B.V. | Composicion farmaceutica para el uso en terapia de sustitucion hormonal. |
| EP1390041B1 (en) | 2001-05-23 | 2009-11-25 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| PT1390042E (pt) | 2001-05-23 | 2008-03-10 | Pantarhei Bioscience Bv | Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal |
| WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| US8026228B2 (en) * | 2001-11-15 | 2011-09-27 | Pantarhei Bioscience B.V. | Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
| AU2002343249B2 (en) | 2002-02-21 | 2009-02-05 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin B12 |
| US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| WO2003103684A1 (en) | 2002-06-11 | 2003-12-18 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| AU2003274941A1 (en) | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| AU2003253506A1 (en) | 2002-07-12 | 2004-02-02 | Pantarhei Biosciences B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| ATE345804T1 (de) | 2002-08-28 | 2006-12-15 | Robert Casper | Estrogenersatztherapie |
| DE60318092T2 (de) | 2002-10-23 | 2008-11-27 | Pantarhei Bioscience B.V. | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung |
| DE60330888D1 (de) | 2002-11-05 | 2010-02-25 | Bayer Schering Pharma Ag | Verwendung von drospirenon zur behandlung von hypertension |
| ES2346053T3 (es) | 2002-11-08 | 2010-10-08 | Pantarhei Bioscience B.V. | Sintesis de esterol a traves de esteroides derivados de estrona. |
| DK1624878T3 (da) | 2003-05-22 | 2007-01-08 | Pantarhei Bioscience Bv | Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte |
| WO2005030175A1 (en) | 2003-09-29 | 2005-04-07 | Novo Nordisk Femcare Ag | Hrt formulations |
| WO2005030176A1 (en) | 2003-09-29 | 2005-04-07 | Novo Nordisk Femcare Ag | Improved stability of progestogen formulations |
| EP1535618A1 (en) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| CN1557291A (zh) * | 2004-01-14 | 2004-12-29 | 杨喜鸿 | 那格列奈分散片及其制备方法 |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
| DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| PT1755562E (pt) | 2004-05-28 | 2013-12-26 | Richter Gedeon Nyrt | Contraceptivo contendo ácido fólico |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| ES2388297T3 (es) | 2005-05-26 | 2012-10-11 | Abbott Products Gmbh | Inhibidores de 17-HSD1 y STS |
| US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
| US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| MX2008011074A (es) | 2006-03-02 | 2008-09-10 | Warner Chilcott Co Inc | Metodo anticonceptivo oral multifasico de ciclo prolongado. |
| US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
| US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
| MX2008014941A (es) | 2006-06-08 | 2008-12-10 | Warner Chilcott Co Inc | Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada. |
| MX2009000256A (es) | 2006-07-06 | 2009-02-18 | Bayer Schering Pharma Ag | Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas. |
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| WO2008067387A2 (en) | 2006-11-29 | 2008-06-05 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
| WO2008079245A2 (en) | 2006-12-20 | 2008-07-03 | Duramed Pharmaceuticals, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| US8236785B2 (en) | 2007-01-08 | 2012-08-07 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
| BRPI0806543A2 (pt) | 2007-01-12 | 2014-04-22 | Wyeth Corp | Composições de comprimido em comprimido |
| ATE537833T1 (de) | 2007-06-21 | 2012-01-15 | Pantarhei Bioscience Bv | Behandlung des mekoniumaspirationssyndroms mit östrogenen |
| US8518923B2 (en) | 2007-07-19 | 2013-08-27 | Pantarhei Bioscience B.V. | Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation |
| JP5399749B2 (ja) * | 2008-03-27 | 2014-01-29 | 沢井製薬株式会社 | プロトンポンプ阻害剤を含有する被覆微粒子 |
| WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
| DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
| BRPI1011815A2 (pt) | 2009-06-23 | 2016-03-29 | Bayer Pharma AG | "composição farmacêutica para a contracepção de emergência" |
| CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
| MX356702B (es) | 2010-04-15 | 2018-06-11 | Bayer Ip Gmbh | Formas de dosificación sólidas orales con dosis muy bajas para la hrt. |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| WO2012055840A1 (en) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| JP2012240917A (ja) | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
| WO2012164095A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
| AU2012264602B2 (en) | 2011-06-01 | 2017-03-09 | Estetra Srl | Process for the production of estetrol intermediates |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| WO2013012326A1 (en) | 2011-07-19 | 2013-01-24 | Pantarhei Bioscience B.V. | Tablet containing dehydroepiandrosterone (dhea) |
| EP2741824B1 (en) | 2011-08-11 | 2017-05-03 | Estetra S.P.R.L. | Use of estetrol as emergency contraceptive |
| MX345674B (es) | 2011-09-16 | 2017-02-10 | Ferring Bv | Composicion farmaceutica de disolucion rapida. |
| AU2012320423C1 (en) | 2011-10-07 | 2018-01-25 | Estetra Srl | Process for the production of estetrol |
| EP2790688B1 (en) | 2011-12-13 | 2019-11-20 | Arstat, Inc. | A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen |
| EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
| WO2014159377A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
| JP6126456B2 (ja) | 2013-05-17 | 2017-05-10 | 東和薬品株式会社 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
| AU2014268779A1 (en) | 2013-05-21 | 2016-01-21 | Predictive Therapeutics, LLC | Therapeutic and method of use |
| WO2015040051A1 (en) | 2013-09-18 | 2015-03-26 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
| WO2015086643A1 (en) | 2013-12-12 | 2015-06-18 | Donesta Bioscience B.V. | Orally disintegrating solid dosage unit containing an estetrol component |
| WO2016023009A1 (en) | 2014-08-07 | 2016-02-11 | Wake Forest University Health Sciences | Compositions and methods for clearing a biological sample |
| WO2016053946A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions and methods for maintaining cognitive function |
| WO2016187269A1 (en) | 2015-05-18 | 2016-11-24 | Agile Therapeutics, Inc. | Contraceptive compositions and methods for improved efficacy and modulation of side effects |
| HRP20210668T1 (hr) | 2015-06-18 | 2021-05-28 | Estetra Sprl | Orodisperzibilna tableta koja sadrži estetrol |
| MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| US20160367567A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| UA123099C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована в порожнині рота одиниця дозування, яка містить естетрольний компонент |
| HUE065350T2 (hu) | 2015-06-23 | 2024-05-28 | Laboratorios Leon Farma Sa | Drospirenonalapú fogamzásgátló túlsúllyal érintett nõi beteg számára |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| US20200046729A1 (en) | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
| CA3178181A1 (en) | 2018-02-07 | 2019-08-15 | Estetra Srl | Contraceptive composition with reduced cardiovascular effects |
-
2016
- 2016-06-20 MD MDE20180408T patent/MD3310346T2/ro unknown
- 2016-06-20 HU HUE16733352A patent/HUE054551T2/hu unknown
- 2016-06-20 MA MA44206A patent/MA44206B1/fr unknown
- 2016-06-20 CA CA2988362A patent/CA2988362C/en active Active
- 2016-06-20 SI SI201631150T patent/SI3310346T1/sl unknown
- 2016-06-20 CN CN201680035672.3A patent/CN107750157B/zh active Active
- 2016-06-20 JP JP2017563337A patent/JP6813150B2/ja active Active
- 2016-06-20 PT PT167333525T patent/PT3310346T/pt unknown
- 2016-06-20 HR HRP20210555TT patent/HRP20210555T1/hr unknown
- 2016-06-20 SM SM20210350T patent/SMT202100350T1/it unknown
- 2016-06-20 DK DK16733352.5T patent/DK3310346T3/da active
- 2016-06-20 LT LTEP16733352.5T patent/LT3310346T/lt unknown
- 2016-06-20 EP EP16733352.5A patent/EP3310346B1/en active Active
- 2016-06-20 US US15/737,189 patent/US10888518B2/en active Active
- 2016-06-20 ES ES16733352T patent/ES2877476T3/es active Active
- 2016-06-20 WO PCT/EP2016/064181 patent/WO2016203044A1/en not_active Ceased
- 2016-06-20 RS RS20210486A patent/RS61777B1/sr unknown
- 2016-06-20 PL PL16733352T patent/PL3310346T3/pl unknown
-
2021
- 2021-04-21 CY CY20211100348T patent/CY1124052T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517715A5 (enExample) | ||
| JP2018517718A5 (enExample) | ||
| JP2018521985A5 (enExample) | ||
| Gupta et al. | Recent trends of fast dissolving tablet-an overview of formulation technology | |
| ES2462536T3 (es) | Comprimido orodispersable multicapa | |
| ES2229483T3 (es) | Composiciones farmaceuticas para la liberacion controlada de sustancias activas. | |
| DK2588086T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FLUORO-3- [6- (4-METHYLPIPERAZIN-1-YL) -1H-BENZIMIDAZOL-2-YL] -1H-QUINOLIN-2-ON-LACTATE MONOHYDRATE | |
| US20130028943A1 (en) | Melatonin tablet and methods of preparation and use | |
| JP2018517717A5 (enExample) | ||
| US20110136771A1 (en) | Orally Disintegrating Solid Dosage Forms Comprising Progestin and Methods of Making and Use Thereof | |
| JP2003534270A (ja) | 速放錠及びその製造方法 | |
| Bhatt | Mouth dissolving tablets challenges, preparation strategies with a special emphasis on Losartan potassium–A review | |
| JP2009114113A (ja) | 口腔内崩壊錠及びその製造方法 | |
| JP2000504028A (ja) | 口内薬剤輸送系 | |
| JP6507272B2 (ja) | トファシチニブ口腔内崩壊錠 | |
| HRP20210555T1 (hr) | Orodisperzibilna tableta koja sadrži estetrol | |
| JP7090616B2 (ja) | カルバメート化合物を含む口腔内崩壊錠 | |
| KR20160112012A (ko) | 질내 투여용 속용성 정제 조성물 | |
| JP7057365B2 (ja) | ミドドリンの組成物およびその使用方法 | |
| BR112019027286A2 (pt) | formulação de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| NO329896B1 (no) | Farmasoytisk sammensetning og anvendelse derav | |
| JP2008285434A (ja) | 口腔内速崩壊錠 | |
| CN104869983A (zh) | 醋酸格拉替雷的透粘膜给药 | |
| EP2826465B1 (en) | Orally disintegrating tablet formulations of donepezil | |
| DK2802311T3 (en) | SUBLINGUAL PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIHISTAMIN MEDICINE AND PROCEDURE FOR PREPARING THEREOF |